@article{1a7f0eedbf8f48c1aa5bbefd78636a8e,
title = "Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes",
author = "Preethi Mani and Kiyoko Uno and \{St. John\}, Julie and Stuart Kupfer and Alfonso Perez and Tuzcu, \{E. Murat\} and Hazen, \{Stanley L.\} and Nissen, \{Steven E.\} and Nicholls, \{Stephen J.\}",
note = "Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi, Resverlogix, and Eli Lilly; and is a consultant/advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; consulting fees from AstraZeneca, Pfizer, Merck Schering-Plough, CSL Behring, Boehringer Ingelheim, Takeda, Roche, NovoNordisk, LipoScience, Amgen, Omthera, Reseverlogix, and Anthera; and has received research support from AstraZeneca, Eli Lilly, Amgen, Takeda, Roche, Novartis, Anthera, Resverlogix, and Lipid Sciences. Drs. Perez and Kupfer are employees of Takeda Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",
year = "2015",
month = jul,
day = "21",
doi = "10.1016/j.jacc.2015.05.023",
language = "English",
volume = "66",
pages = "328--329",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "3",
}